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ABSTRACT
Introduction: Breast cancer is ranked first among other cancers in women. Ineffectiveness of current treatments and 
adverse effects such as multiple organ failure and nephrotoxicity are the common problems faced in cancer therapy. 
Therefore, alternatives to treat breast cancer metastasis with fewer toxic effects are actively sought-after. Dillenia 
suffruticosa (DS) commonly known as ‘Simpoh air’ has been a traditional remedy for cancer growth. Therefore, 
this study investigated the metastasis inhibiting properties of DS root dichloromethane extract (DCMDS) in tumour 
bearing female BALB/c mice and sub-acute multiple dose oral toxicity upon treatment with this extract. Methods: 
Forty-eight tumour bearing mice were given either oral treatment of DCMDS (50, 100 and 200 mg/kg) or doxorubicin 
(2 mg/kg) for 28 days and the degree of metastasis was analysed in each group. Thirty other female BALB/c mice were 
treated with DCMDS (50, 100 and 200 mg/kg) and the general behaviours, biochemical, haematological and histo-
pathological changes were observed.  Data were analysed with One-way ANOVA and Dunnet’s test where p<0.05 
was considered significant. Results: All doses of DCMDS showed lowered metastatic cells in liver and DCMDS at 
(50 and 100 mg/kg) had less metastatic cells in the heart compared to doxorubicin (2 mg/kg). All DCMDS treated 
groups showed no abnormal behaviours and all tested physiological parameter values fall within the normal ranges. 
Conclusion: DCMDS reduced metastasis of 4T1 cells to the liver and heart better than doxorubicin without causing 
toxicity. This study highlights that DCMDS is a promising drug to be further developed for cancer therapy.
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Breast cancer ranked the first among other cancers in 
women and the incidence is increasing dramatically 
worldwide. There are several standard treatments for 
patients with breast cancer including radiotherapy, 
chemotherapy, hormone therapy and surgery. 
Nevertheless, they are not effective especially to treat 
breast cancer metastasis (1). Moreover, these treatments 
come with several adverse effects including organ 
failure, immune-suppression and development of drug 
resistance (2-3). 
Doxorubicin is the frontline drug used since 1974 for 
cancer treatment. The Food and Drug Administration 
has approved doxorubicin as one of the most potent 
chemotherapeutic drugs (4). However, though it 
provides cure in some cancer cases, its usage is limited 
due to its toxic effect on non-cancerous cells affecting 
major organs, and could cause cardiotoxicity which is 
life-threatening. Therefore, treatment with doxorubicin 
is only applicable in selected cases (5).
Failure to subsequent therapy and relapse of rapid 
tumour growth are caused by the emergence of tumour 
cells that are resistant to anticancer drugs and other 
types of cancer treatment (6-8). Hence, there are lots 
of efforts in finding alternative for management and 
treatment of breast cancer. Currently, researchers have 
started to search for new alternative of anticancer drugs 
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derived from plants, marine and microorganism (9). It is 
believed that naturally derived anticancer drugs are safe 
(10). However, the necessity for toxicity study of natural 
products increases as there are reports of toxic effects 
upon its consumptions. 
Dillenia suffruticosa (DS) is one of the potential herbs 
with various pharmacological properties. It is locally 
known as ‘Simpoh air’ that can be found in West 
Malaysia, Philippines, Indonesia and Brunei. The 
fruit pulp has been traditionally used as treatment for 
headache and as a wound healing agent (11). The leaves 
are used as traditional remedies to treat microbial and 
fungal infection (12) and the fruit as a treatment for 
cancerous growth (13). 
The methanol root extract of DS exhibited antioxidant 
activities and cytotoxicity towards several cancer cell 
lines especially HeLa. The dichloromethane and ethyl 
acetate extract of DS exhibited strong cytotoxicity 
towards selected cancer cell lines such as HeLa, MCF-7, 
A549, MDA-MB-231 and HT29 by initiating apoptosis 
and cell cycle arrest (14). The phytochemical studies 
suggest the constituents of saponins, terpenoids, sterols 
and polyphenolic compounds that contribute to the 
cytotoxic properties (15). DS root dichloromethane 
extract (DCMDS) exhibited cytotoxicity, induced cell 
cycle arrest and apoptosis towards MCF-7 and MDA-
MB-231 breast cancer cell lines (16-17). DCMDS 
exhibited the potential of targeting cancer cells with 
mutant caspase-3 (MCF-7) by induction of cell cycle 
arrest and apoptosis via multiple signaling pathways 
(16). Betulinic acid was reported to be the main 
cytotoxic compound in DCMDS (17). Betulinic acid 
has various polypharmacological activities that include 
antiretroviral, antimalarial, anti-inflammatory and 
anti-cancer (18-22). The aqueous extract of DS root 
possessed anti-breast cancer properties (23) and might 
be an effective therapy to treat this condition. 
Even though the anti-breast cancer properties of 
DCMDS have been reported, its ability to inhibit 
cancer metastasis to other adjacent organs remains 
unexplored. Since recently used anti-cancer therapy are 
companied with complications such as multiple organ 
failure (24) and nephrotoxicity (25), it is important to 
outline the safety margin of this drug ensure that it is 
not potentially harmful to the host. Therefore, this study 
determined the metastasis inhibition property of DS root 
dichloromethane extract (DCMDS) in tumour bearing 
female BALB/c mice and the possible sub-acute multiple 
dose oral toxicity of DCMDS.
MATERIALS AND METHODS
Dillenia suffruticosa
The fine powder of root of DS was supplied by 
Primer Herber Sdn. Bhd., Malaysia. Identification and 
authentication of the plant was done at the Biodiversity 
Unit, Institute of Bioscience, UPM (Voucher specimen 
number SK 1937/11).
Preparation of DCMDS 
Briefly, 150 g of fine powder of the root of DS was 
macerated with dichloromethane. Then, the mixture was 
filtered using Whatman filter paper No. 1. Residues of the 
mixture were re-extracted with dichloromethane three 
times. The filtrates were pooled and dichloromethane 
was eliminated using a rotary evaporator at 40°C. The 
extract was weighed and stored at -20°C. The percentage 
of yield was then calculated using the following formula:
Yield (%)=     (Weight of crude extract)          X 100
      (Weight of dried plant materials)
Cell culture
The 4T1 mouse mammary carcinoma cells were 
cultured in RPMI 1640 medium supplemented with 
10% fetal bovine serum (FBS) and 1% of antibiotics (100 
µg/mL penicillin and 100 µg/mL streptomycin). The cells 
were maintained in a humidified atmosphere at 37°C 
containing 5% of carbon dioxide.
Experimental animal
The protocol of the study was reviewed and approved 
by the Institutional of Animal Care and Use Committee 
(IACUC) of Universiti Putra Malaysia (UPM/IACUC/
AUP-R068/2015). Female 6-8 weeks old BALB/c mice 
with 20–30 g in weight were used in this study. They 
were housed in individual cages with a period of 12-h 
light and 12-h dark cycle, in a room with temperature 
set at 20–24ºC with 40%–50% relative humidity. All 
the mice were acclimatized for at least a week before 
starting the experiment. The mice were fed with a 
standard food pellet (Gold Coin, Malaysia) and were 
provided with tap water ad libitum.
Experimental design
In vivo anti-breast cancer study of DCMDS
Forty-eight female BALB/c mice were allocated into six 
groups (n=8), which were negative control (with breast 
cancer, untreated), positive control (with breast cancer, 
treated with doxorubicin 2 mg/kg), normal control 
(without breast cancer, untreated) and another three 
groups of mice with breast cancer, treated with 50 mg/
kg, 100 mg/kg and 200 mg/kg of DCMDS, respectively, 
except for the normal control. All mice were injected 
with 4T1 cells (1 x 105 4T1 cells/0.1 mL of PBS) into 
the mammary fat pad. When the tumour was palpable, 
DCMDS was administered orally to the animals via 
gavage for 28 days.
The mice were weighed three times a week. The tumour 
volume was measured twice weekly by using a digital 
vernier caliper. The following formula was used to 
determine the volume of the tumours (26):
Volume of the tumours = Length x width2 x 0.52
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Mortality of the mice was recorded to calculate the 
survival time. The major organs (heart, kidneys, spleen, 
liver, lungs) were excised for fats, weighed and subjected 
to gross observation. The organ- to- body weight ratio of 
each mouse was calculated.
Sub-acute toxicity study of DCMDS
Thirty female BALB/c mice were assigned in a random 
way into five groups (n=6), which were the normal and 
negative control, and three treatment groups of escalating 
dose of DCMDS (50, 100 and 200 mg/kg). The doses 
were selected based on solubility test and acute toxicity 
study. The negative control group received 10% DMSO. 
For the treatment groups, DCMDS was dissolved in 10% 
DMSO and orally administered daily for 28 days. The 
animals were monitored twice daily (before and after 
dosing) for general health such as general appearance, 
behaviour, toxicity symptoms and mortality in 28 days. 
The body weight was measured at a time interval of 
three days (Day 1, 4, 7, 10, 13, 16, 19, 22, 25 and 28).
Biochemical and haematological analysis
Blood collection was carried out on Day 29 in the 
sub-acute toxicity study. Prior to blood collection, the 
mice were anesthetized under ketamine (75 mg/kg; 
ip) and xylazine (5 mg/kg; ip). The blood samples (1 
mL) were collected by cardiac puncture by using a 26 
G x 1/2 needle” (Terumo®, Belgium) and centrifuged 
at 10000 rpm for 10 minutes to separate the serum. 
Blood biochemical and haematological analysis were 
carried out by using a chemistry analyser (Selectra XL, 
Dieren, Netherlands) and hematoanalyser, respectively. 
For liver hepatic function, level of serum alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST) and alkaline phosphatise (ALP) was evaluated. For 
kidney renal function, blood urea nitrogen and serum 
creatinine level was determined.
Histopathological observation
Following blood sampling, the mice were sacrificed. 
Tumours and organs including heart, lungs, kidneys, 
liver and spleen were harvested and placed in 10% 
formalin fixative. After fixation for at least 24 hours, the 
tissues were processed for 16 hours by an automated 
tissue processor (Leica ASP6025, Leica Microsystems, 
Wetzlar, Germany). The processed tissues were then 
embedded into paraffin blocks. Five micrometres 
thick sections were cut and stained with haematoxylin 
and eosin (H&E). Each slide was examined under a 
light microscope with guidance of a pathologist. The 
histological changes were evaluated by from 10 random 
fields from each slide of each group.
For the sub-acute, multiple dose toxicity study, the 
scoring system for histological changes of liver and 
kidney was based on degree of necrosis of hepatocytes, 
chromatin condensation, light cytoplasm, nucleus 
fragmentation, and sinusoidal widening in liver while 
degree of dilation in the glomeruli and tubular necrosis 
in kidney (27).
For the anti-breast cancer study, the slides were viewed 
for any metastatic cell and any organ that had one 
metastatic cell, and later recorded as “with metastasis”.
Statistical data analysis
The data were analysed by Graphpad prism 5.0. One 
way ANOVA analyses were performed followed by 
Dunnet’s test. The data were presented as mean ± SEM. 
Value of p<0.05 was considered as significant.
RESULTS
Anti-breast cancer properties of DCMDS
Effects of DCMDS on the body weight and relative 
organ weight in tumour-bearing female BALB/c mice
Body weight changes and relative organ weight of 
tumour-bearing female BALB/c mice are shown in Fig. 
1A and 1B, respectively. There were no significant 
fluctuations in the body weight and relative organ 
weight of all the DCMDS-treated groups compared to 
the normal control group (p>0.05).
Figure 1: (A) Body weight (B) Relative organ weight of 4T1 
tumour-bearing female BALB/c mice treated with DCMDS 
for 28 days. Each column represents the mean ± S.E.M. of 
six mice. *p<0.05 compared with the control group (one-way 
Anova followed by Dunnett’s test).
Effects of DCMDS on the tumour volume and survival 
rate in tumour-bearing female BALB/c mice
Tumour volume and survival rate of tumour-bearing 
female BALB/c mice are shown in Fig. 2 and 3, 
respectively. There were no significant changes in 
the tumour volume of all the DCMDS-treated groups 
compared to the negative and positive control groups 
(p>0.05). There was no apparent difference in the survival 
prolongation between the DCMDS-treated groups and 
both the control groups (log-rank test, p>0.05). 
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Effects of DCMDS on metastasis in tumour-bearing 
female BALB/c mice
Lungs of the tumour-bearing female BALB/c mice given 
DCMDS treatment are shown in Fig. 4. The group 
treated with doxorubicin has the least number of tumour 
nodules. Less number of tumour nodules was noted in 
the treatment with 200 mg/kg of DCMDS compared to 
50 and 100 mg/kg DCMDS-treated groups. Fig. 5 shows 
the presence of metastatic cells that appeared in clusters 
in the liver and heart sections of 4T1- tumour-bearing 
female BALB/c mice. All doses of DCMDS showed 
lowered metastatic cells in liver and DCMDS at (50 
and 100 mg/kg) had less metastatic cells in the heart 
compared to doxorubicin (2 mg/kg).
Sub-acute multiple dose oral toxicity of DCMDS
Effects of DCMDS on the body weight and relative 
organ weight of female BALB/c mice
Changes in the mean body weights values of female 
BALB/c mice treated with DCMDS for 28 days are 
illustrated in Fig. 6A. There was no significant difference 
in the body weight of all the DCMDS-treated groups 
compared to the normal control group (p>0.05) 
throughout the experimental period. Fig. 6B illustrates 
various organs to body weight ratio (kidneys, liver, 
spleen, heart and lungs) of female BALB/c mice treated 
with DCMDS. There was no significant difference in the 
organs to body weight ratio of all the DCMDS-treated 
groups compared to the normal control group (p>0.05) 
throughout the experimental period.
Effects of DCMDS on the biochemical parameters and 
haematological profile in female BALB/c mice
Level of liver enzymes, kidney functions and complete 
blood profile of female BALB/c mice given DCMDS 
Figure 2: Tumour volume of 4T1 tumour-bearing female BAL-
B/c mice treated with DCMDS for 28 days. Each column rep-
resents the mean ± S.E.M. of six mice. *p<0.05 compared 
with the control group (one-way Anova followed by Dunnett’s 
test).
Figure 3: Survival rate of 4T1 tumour-bearing female BALB/c 
mice treated with DCMDS for 28 days.
Figure 4: Lungs of 4T1 tumour-bearing female BALB/c mice 
treated with DCMDS for 28 days. The tumour nodules (white 
spots) are metastasized from breast cancer cells. 
Figure 5: (A) Liver (B) Heart sections of 4T1-tumor-bearing 
female BALB/c mice treated with (I) doxorubicin 2 mg/kg, 
(II) DCMDS 50 mg/kg, (III) DCMDS 100 mg/kg, (IV) DCMDS 
200 mg/kg as observed under a light microscope after stain-
ing with hematoxylin and eosin. The livers and hearts of 4T1 
tumour-bearing mice showed infiltration of neoplastic cells. 
The cells were poorly differentiated and characterized by the 
presence of large hyperchromatic nuclei and small amount of 
cytoplasm. Metastatic cells that appeared in cluster are marked 
by M (40X magnification). Scale bar represents 100 µm.
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treatment is shown in Table I. There was a significant 
decrease in the level of ALP in the group of 50 and 
200 mg/kg of DCMDS and negative control compared 
to the normal control group (p<0.05). There were no 
significant changes in the complete blood profile of all 
the DCMDS-treated groups compared to the normal 
control group (p>0.05). 
DISCUSSION
Since currently available anti-cancer agents exert un-
desired health issues, the potential of DCMDS as an-
ti-breast cancer agent has been investigated alongside 
the possible toxic effect of this extract. The anti-breast 
cancer and cancer metastasis properties of DCMDS 
were determined using the 4T1 tumour-bearing BALB/c 
mice model. The model worked whereby the cancer de-
veloped after seven days of induction. In addition, it was 
also evidenced by the higher relative spleen weight of 
the 4T1 tumour-bearing mice compared to the normal 
mice. The spleen harvested from the 4T1 tumour-bear-
ing mice showed sign of splenomegaly (the enlargement 
of the spleen)(data not shown), which is the change in 
splenic architecture due to the presence of tumour that 
increased the circulating neutrophils and other leuko-
cytes (mature blood cells) and the occurrence of extra-
medullary hematopoiesis (28). 
The weight of the tumour-bearing mice in all groups in-
creased after 2 weeks of induction except for the positive 
control group (2 mg/kg doxorubicin) probably due to 
the side effects of the drug that causes reduced appetite, 
hence reduced body weight. Even though insignificant, 
a reducing trend in the body weight was noted start-
ing from day 4 until day 13 for the negative control, 50 
and 100 mg/kg of DCMDS-treated groups, and from day 
1 until day 7 for 200 mg/kg of DCMDS-treated group. 
The reason behind the condition remains unclear. UK 
Home Office Regulation reported that weight loss is ex-
pected in tumour-bearing mice after 4 weeks of breast 
cancer induction and the mice could lose up to 25% of 
their body weight (29). Nevertheless, in this study, the 
weight loss occurred as early as 7 days after induction. 
It is believed due to the use of higher concentration of 
4T1 cells i.e. 5 x 105 / 0.1 mL cold PBS as compared to 
1 x 105 / 0.1 mL cold PBS (29) that causes the cancer 
to be developed faster and more aggressive. This per-
haps will bring more pain that will lead to stress, which 
will suppress the appetite. Loss of appetite will make the 
animals to consume less food and therefore reduce the 
body weight. The animals also presented some features 
of cancer-anorexia cachexia syndrome or defined as 
wasting syndrome, which involves muscle mass and fat 
loss directly instigated by tumour factors or indirectly by 
an unusual response by host to the presence of tumour 
(30). 
In this experiment, doxorubicin was used as a positive 
control. Doxorubicin is one of the chemotherapeutic 
drugs used to treat metastatic breast cancer. The complex 
mechanism of action of doxorubicin includes blocking 
of topoisomerase II production and induction of DNA 
double-strand breaking, interference in the unwinding 
of DNA, initiation of differentiation, and production of 
reactive oxygen species (31). Among all the treatment 
groups, doxorubicin at 2 mg/kg was found to be the 
most potent only for inhibition of metastasis to the lungs, 
the first organ that the cancer cells will spread to due to 
its near distance to the breast. This is proven by the least 
number of tumour nodules (metastatic cells) detected 
in the lungs based on the macroscopic observation as 
compared to other groups. The other reason of doxoru-
bicin giving the best effect is probably due to the route 
of administration, which is via intraperitoneal injection. 
Absorption of substance delivered intra-peritoneally (IP) 
is usually much slower than for intra-venous (IV) injec-
tion but it is delivered faster compared to oral adminis-
tration (32). Even though the absorption of the delivered 
material is faster for IP injection as compared to oral ad-
ministration, the pharmacokinetics of substances in both 
IP and oral administration are the same due to the main 
route of absorption is via mesenteric vessels, which is 
moved into the portal vein and pass through the liver 
(33). Thus, it is believed that IP administration of doxo-
rubicin helps to give the good effect of the drug delivery 
to targeted sites (breast). Data of this in vivo study further 
support the antibreast cancer properties of DCMDS to-
wards MCF-7 and MDA-MB-231 breast cancer cell lines 
(16-17). DCMDS is therefore a very potent option to be 
Figure 6: (A) Body weight (B) Organ to body weight ratio of 
female BALB/c mice treated with DCMDS in the sub-acute 
toxicity study for 28 days. *p<0.05 compared with the control 
group (one-way Anova followed by Dunnett’s test).
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further explored as breast cancer therapy.
The possible toxic effect that might be exerted by DC-
MDS was evaluated from sub-acute multiple dose tox-
icity study where female BALB/c mice were on repeated 
oral administration of DCMDS for 28 days. The sub-
acute oral toxicity serves as an essential test for assess-
ing safety (34). An ingested item will be transported to 
the liver for detoxification and kidney for urea removal 
by the blood. Therefore a high toxic level would be in-
dicated in the blood and the detrimental effect of the 
drug will affect the function of those organs. The sub-
acute multiple dose oral toxicity screening for the blood 
profile, organ function and histopathological effect of 
the organs will be able to provide us with the necessary 
information on the toxic effect of DCMDS. There were 
no deaths due to the employed treatment and signs of 
morbidity at any dose level of DCMDS tested (50, 100 
and 200 mg/kg). All the animals were absent from any 
abnormal symptoms such as restlessness, unresponsive-
ness and failure to groom. General performance or ac-
tivity and body weight are one of the important parame-
ters for evaluation of first signs of toxicity (35).
In addition, the treated animals showed no significant 
weight loss throughout the experiment, suggesting 
that they are free from any adverse effects of DCMDS. 
Changes in the body weight of an animal are measure 
of an unfavourable effect of a drug or the chemical to 
be tested (36). The DCMDS treatment groups were hav-
ing percentage of organ to body weight ratio of kidneys, 
spleen, liver, heart and lungs similar to the normal con-
trol suggesting that DCMDS does not injure or affect any 
organ development of the animals. This is supported by 
(37), whereby relative organ weight is one of the indi-
cations to detect if the organs have been attained some 
form of injury. 
The plasma level of liver enzymes (ALT and AST) of DC-
MDS-treated groups was in the normal range. Liver is 
the main organ associated with the biotransformation 
of drugs (38). Liver is very prone to xenobiotic-induced 
injury due to its principal role in metabolism of xeno-
biotic (39). Biomarkers of the serum levels of liver en-
zymes are able to represent liver health. As mentioned 
by (40), hepatotoxin and drugs that are toxic to the liver 
causes a hike in the level of serum AST, ALT and ALP. 
ALT specifically detects liver health and therefore is a 
better parameter to identify liver injury. Possible disease 
to muscles and heart could cause changes to AST lev-
els (41). ALT, a cytoplasmic enzyme is present at high 
levels in the liver and a rise in the concentration of this 
enzyme indicates hepatocellular damage (42). In con-
trast to ALT, ALP is found commonly at the cell lining 
of bile duct in the liver and is useful in the detection 
of any blockade to the biliary system (43). Even though 
there was a significant drop in the level of ALP in the 
groups treated with 50 and 100 mg/kg of DCMDS, the 
histopathological observation revealed no abnormalities 
in the liver.
There was no significant difference in both urea and cre-
atinine serum levels in all of the DCMDS-treated groups 
compared to the normal control group suggesting that 
the extract does not cause any toxicity to the kidney 
and alter the renal functions. Urea and creatinine lev-
els could effectively indicate kidney dysfunction (44) 
and the elevation in the blood creatinine indicates a re-
duced kidney function (45). Creatinine is the product of 
the catabolism of phosphate in skeletal muscle and will 
increase when renal function is poor (46). As for the se-
rum urea, it can increase due to the toxic effect on renal 
parenchyma, renal tubules and a possible block in the 
urinary outflow tract (47). 
Treatment with DCMDS also did not affect the haemato-
logical profile of the animals including red blood cells, 
white blood cells, haemoglobin, packed cell volume, 
mean corpuscular haemoglobin, mean corpuscular vol-
ume, platelet and plasma protein. According to (44), 
hematopoietic system, a sensitive target for compounds 
that are toxic serves as a vital index of its functional and 
pathological status. It is suggested that DCMDS does 
not affect the physiological function of the animals. As 
suggested by (48), blood parameters analysis is appro-
priate for evaluation of risk of toxicity, as alterations to 
the haematological systems could highly predict human 
toxicity from the outcome of animal study is translated 
to human use. 
From the histopathological observation, the liver tissue 
from all the DCMDS-treated groups did not show any 
sign of abnormalities such as necrosis, inflammatory 
cell infiltration and haemorrhage, similar to the nor-
mal control. It is suggested that DCMDS is not toxic to 
the liver, in agreement with the data on level of serum 
ALT, AST and ALP. This is supported by (37) that the 
impaired organs often have abnormal atrophy. Gross ex-
aminations after post-mortem dissection of the animals 
further confirmed that DCMDS did not cause any organ 
damage as all the organs are normal in size and have 
similar structural architecture with the normal control. 
As for the kidney tissue, there was also absence of any 
histological changes or abnormalities such as necrosis, 
inflammatory cell infiltration and haemorrhage in all the 
DCMDS-treated groups, similar to the normal control 
group, which indicates the absence of toxicity. The gross 
examinations of kidneys also revealed no abnormality, 
and the relative organ weight of kidneys was indifferent 
compared to the control. It is suggested that DCMDS is 
not toxic to the kidneys, in agreement with the data on 
level of serum creatinine and urea.
Considering that DCMDS showed lower cancer metas-
tasis compared to doxorubicin and recorded no toxic 
effect to the vital organs such as kidney and liver, it is 
a potential candidate for the treatment of breast cancer 
therapy. 
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CONCLUSION
DCMDS has reduced the severity of metastasis to the liver 
and heart of 4T1 tumour-bearing female BALB/c mice 
better than doxorubicin. Based on the normal behaviour, 
body weight, organ to body weight ratio, biochemical 
profile, haematological profile and organ histology 
from the sub-acute multiple dose oral toxicity study, 
the treatment with 50, 100 and 200 mg/kg DCMDS was 
not toxic to the animals. DCMDS also was considered 
safe when given orally to the animals in repeated dose. 
DCMDS is therefore a highly potential agent to be 
established for breast cancer therapy. However, more 
research is necessary to further elucidate the exact 
mechanism of action of this drug and its therapeutic 
value in other types of cancer. Furthermore, its effect 
should also be compared with other currently available 
anti-cancer drugs to evaluate if DCMDS is a promising 
substitute to the present cancer therapy.
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